A Study of ICP-192 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT04565275

Public ClinicalTrials.gov record NCT04565275. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations

Study identification

NCT ID: NCT04565275
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Beijing InnoCare Pharma Tech Co., Ltd.; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Interventions

Drug ICP-192 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2021
Primary completion: Nov 29, 2023
Completion: Apr 14, 2024
Last update posted: Mar 13, 2023

2021 – 2024

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
Arizona Oncology	Tucson	Arizona	85711	Recruiting
University of California, San Diego (UCSD) - Moores Cancer Center	La Jolla	California	92037	Recruiting
Rocky Mountain Cancer Centers	Aurora	Colorado	80012	Recruiting
Mid Florida Hematology and Oncology	Orange City	Florida	32763	Not yet recruiting
Minnesota Oncology Hematology	Minneapolis	Minnesota	55404	Recruiting
Clinical Research Alliance	Lake Success	New York	11042	Recruiting
Rutgers Cancer Institute of New Jersey	The Bronx	New York	10462	Recruiting
The Ohio State University	Columbus	Ohio	43210	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77001	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04565275, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 13, 2023 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04565275 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →